Pharma Blog Watch

New Acomplia Data (QDIS Blog)
In his blog, Ed Vawter discusses an announcement by sanofi-aventis that its weight-loss drug Acomplia (rimonabant) helped control blood sugar levels in Type 2 diabetes patients. The drug is approved in many European countries and in Mexico but not in the U.S. "It will be interesting to see where this goes since the FDA issued an approvable letter and sanofi gave their response. There really isn't much there just that they will work closely with the FDA on its future development."

"My best guess is this won't have any impact on the questions the FDA asked since this study was likely under way long before the Feb. approvable letter from the FDA," he writes.